There are limited treatment options for @entity320 , which is almost universally fatal. We report the successful treatment of 64 of 64 cutaneous and subcutaneous @entity320 metastases in three @entity1 using high-dose (22 million units per 1.2 ml) intralesional @entity1199 ( @entity1199 ) in combination with topical imiquimod and a retinoid cream. Before intralesional therapy, all @entity1 had been treated surgically and were no longer considered surgical candidates. Rebiopsy of 15 of the treatment sites and long-term follow-up (10, 12, and 27 months) showed regression of all treated @entity5 . Six months after discontinuation of therapy, one @entity1 developed multiple new cutaneous metastases, but these were also responsive to treatment with intralesional therapy. The other two @entity1 did not experience recurrence of their cutaneous @entity320 . However, one of the two @entity1 developed lymph node and brain metastases 18 months after initiation of intralesional therapy, but is still alive, now at 27 months. The concentration of @entity1199 used for the intralesional therapy was much higher than in previously reported cases, which may explain the excellent responses that were observed. These results support intralesional high-dose @entity1199 as a very effective therapy for controlling cutaneous @entity320 . Additional studies are needed to determine whether this therapy is associated with a survival benefit.

Complete regression of subcutaneous and cutaneous @entity320 with high-dose intralesional XXXX in combination with topical imiquimod and retinoid cream.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1199 :: ('3558', 'Gene') :: ['IL-2', 'interleukin 2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma']
@entity1199 :: (3558,Gene) :: ['interleukin 2']
